“In the Phase 2 portion of the waveLINE-003 trial, the 1.75 mg/kg dose of zilovertamab vedotin with rituximab, gemcitabine and oxaliplatin demonstrated a promising response rate, complete ...

About 25% were prescribed Wegovy or another GLP-1 medication, said Dr. Thao-Ly Phan, the clinic’s medical director. The number of adolescents with a GLP-1 prescription nearly doubled from 2023.

Please provide your email address to receive an email when new articles are posted on . Sotagliflozin improved HbA1c and body weight for patients with type 2 diabetes. The treatment effect varied ...

Continuing high prices and demand for GLP-1 weight-loss drugs is creating lots ... which treats diabetes, and Wegovy, sold for obesity, were on the Food and Drug Administration’s list of drugs ...

Experts urge regular GP check ups amid complaints of drug-induced hepatitis by users of Ozempic, Wegovy and Mounjaro, known as GLP-1 agonists. Complaints of flu-like symptoms, fatigue, crippling ...

Some consumers are taking smaller than standard doses of GLP-1s—the popular class of weight-loss and diabetes drugs that include Ozempic, Wegovy, and Zepbound—or spacing out doses longer than ...

In January 2025, Cocrystal Pharma, Inc. (NASDAQ:COCP) announced results from the Phase 1 trial of CDI-988 for ... cohort that will receive a dose of 1,200 mg and a shorter treatment duration ...

Novo Nordisk (NVO) announced Friday that a higher-dose version of its popular obesity therapy, semaglutide, marketed as Wegovy led to ... as semaglutide 7.2 mg caused a significant and superior ...

Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist, which works by promoting the release of insulin and inhibiting the release of glucagon, helping to keep blood sugar levels stable.